The risk of urolithiasis recurrence may be reduced with anti-nanobacterial therapy

Medical Hypotheses

Volumn 68, Issue 6, 2007, Pages 1348-1350

  Silay, Mesrur Selcuk ^a,b   Miroglu, Cengiz ^b  

^a HOUSTON METHODIST HOSPITAL   (United States)

^b SISLI ETFAL TRAINING AND RESEARCH HOSPITAL   (Turkey)

Author keywords

[No Author keywords available]

Indexed keywords

AMINOCAPROIC ACID; AMINOGLYCOSIDE ANTIBIOTIC AGENT; AMPICILLIN; ANTIBIOTIC AGENT; BISPHOSPHONIC ACID DERIVATIVE; CITRATE POTASSIUM; CITRIC ACID; COTRIMOXAZOLE; EDETIC ACID; FLUOROURACIL; NITROFURANTOIN; NUTRACEUTICAL; TETRACYCLINE; TRIMETHOPRIM; VANCOMYCIN;

ARTERY CALCIFICATION; ARTICLE; BACTERICIDAL ACTIVITY; BACTERIUM CULTURE; COMBINATION CHEMOTHERAPY; CORONARY ARTERY DISEASE; DRUG PENETRATION; GRAM NEGATIVE BACTERIUM; HUMAN; NANOBACTERIUM; NEPHROLITHIASIS; NONHUMAN; POSTMENOPAUSE OSTEOPOROSIS; PRIORITY JOURNAL; PROSTATE DISEASE; RECURRENT DISEASE; RISK FACTOR; STONE FORMATION; TRANSRECTAL ULTRASONOGRAPHY; TREATMENT OUTCOME; UROLITHIASIS;

ANTI-BACTERIAL AGENTS; CLINICAL TRIALS; FEMALE; GRAM-NEGATIVE BACTERIA; HUMANS; MALE; MODELS, BIOLOGICAL; NANOTECHNOLOGY; RECURRENCE; RISK FACTORS; UROLITHIASIS;

EID: 33947704249     PISSN: 03069877     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.mehy.2006.10.027     Document Type: Article

References (21)

1. Stamatelou K.K., Francis M.E., Jones C.A., et al. Time trends in reported prevalence of kidney stones in United States: 1976-1994. Kidney Int 63 (2003) 1817-1823
2. JC L., Pena de la Vega L.S., Slezak J.M., et al. Renal stone epidemiology in Rochester, Minnesota: an update. Kidney Int 69 (2006) 760-764
3. Hesse A., Brandle E., Wilbert D., et al. Study on the prevalence and incidence of urolithiasis in Germany comparing the years 1979 vs. 2000. Eur Urol 44 (2003) 709-713
4. Pearle M.S., Calhoun E.A., and Curhan G.C. Urologic diseases in America project: urolithiasis. J Urol 173 (2005) 848-857
5. Saigal C.S., Joyce G., and Timilsina A.R. Direct and indirect costs of nephrolithiasis in an employed population: opportunity for disease management?. Kidney Int 68 (2005) 1808-1814
6. Tiselius H., Ackerman D., Alken P., Buck C., Conort P., and Galluci M. Working party on lithiasis, European association of urology. Guidelines on urolithiasis. Eur Urol 40 (2001) 362-371
7. Miller V.M., Rodgers G., Charlesworth J.A., et al. Evidence of nanobacterial-like structures in calcified human arteries and cardiac valves. Am J Physiol Heart Circ Physiol 287 (2004) H1115
8. Altundag K., Silay Y.S., Altundag O., Atik M.A., and Aktolga S. Bisphosphonate use for osteoporosis in postmenopausal women may inhibit occurrence of malignant microcalcification in breast tissue. Med Hypotheses 67 (2006) 202-203
9. Puskas L.G., Tiszlacicz L., Razga Z., Torday L.L., Krenacs T., and Papp J.G. Detection of nanobacteria-like particles in human atherosclerotic plaques. Acta Biol Hung 56 (2005) 233-245
10. Ciftcioglu N., McKay D.S., and Kajander E.O. Association between nanobacteria and periodontal disease. Circulation 108 (2003) e58-e59
11. Kajander E.O., Ciftcioglu N., Millaer-Hjelle A.M., and Hjelle J.T. Nanobacteria: controversial pathogens in nephrolithiasis and polycystic kidney disease. Curr Opin Nephrol Hypertens 10 (2001) 445
12. Wood H.M., and Shoskes D.A. The role of nanobacteria in urologic disease. World J Urol 24 (2006) 51-54
13. Shiekh F.A., Khullar M., and Singh S.K. Lithogenesis: induction of renal calcifications by nanobacteria. Urol Res 34 (2006) 53-57
14. Akerman K.K., Kuikka J.T., Ciftcioglu N., et al. Radiolabelling and in vivo distribution of nanobacteria in rabbit. Proc SPIE Int Soc Opt Eng 3111 (1997) 436
15. Ciftcioglu N., Bjorklund M., Kuorikoski K., et al. Nanobacteria: an infectious cause for kidney stone formation. Kidney Int 56 (1999) 1893
16. Khullar M., Sharma S.K., Singh S.K., et al. Morphological and immunological characteristics of nanobacteria from human renal stones of a north Indian population. Urol Res 32 (2004) 190
17. Garcia Cuerpo E., Kajander E.O., Ciftcioglu N., et al. Nanobacteria. An experimental neo-lithogenesis model. [in Spanish]. Arch Esp Urol 53 (2000) 291-303
18. Ciftcioglu N., Miller-Hjelle M.A., Hjelle J.T., and Kajander E.O. Inhibition of nanobacteria by antimicrobial drugs as measured by a modified microdilution method. Antimicrob Agents Chemother 46 (2002) 2077
19. Silay Y.S., Altundag K., Altundag O., Atik M.A., and Ozen M. Bisphosphonates may inhibit development of atherosclerosis formation through its bactericidal effect on nanobacteria. Med Hypotheses 64 (2005) 1239-1240
20. Maniscalco B.S., and Taylor K.A. Calcification in coronary artery disease can be reversed by EDTA-tetracycline long-term chemotherapy. Pathophysiology 11 (2004) 95-101
21. Shoskes D.A., Thomas K.D., and Gomez E. Anti-nanobacterial therapy for men with chronic prostatitis/ chronic pelvic pain syndrome and prostatic stones: preliminary experience. J Urol 173 (2005) 474-477